Melanoma - Pipeline Review, H1 2018

  • ID: 4586016
  • Drug Pipelines
  • 2011 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4D Pharma PLC
  • Batu Biologics Inc
  • Eisai Co Ltd
  • Immunomedics Inc
  • NantKwest Inc
  • Sanofi
  • MORE
Melanoma - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H1 2018, provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Report Highlights:

This latest pipeline guide Melanoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 19, 116, 125, 1, 9, 217, 30 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 18, 13, 1, 73 and 10 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4D Pharma PLC
  • Batu Biologics Inc
  • Eisai Co Ltd
  • Immunomedics Inc
  • NantKwest Inc
  • Sanofi
  • MORE
Introduction

Melanoma - Overview

Melanoma - Therapeutics Development

Melanoma - Therapeutics Assessment

Melanoma - Companies Involved in Therapeutics Development

Melanoma - Drug Profiles

Melanoma - Dormant Projects

Melanoma - Discontinued Products

Melanoma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Melanoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Melanoma - Pipeline by 4D Pharma PLC, H1 2018

Melanoma - Pipeline by 4P-Pharma SAS, H1 2018

Melanoma - Pipeline by 4SC AG, H1 2018

Melanoma - Pipeline by AB Science SA, H1 2018

Melanoma - Pipeline by AbbVie Inc, H1 2018

Melanoma - Pipeline by Abivax SA, H1 2018

Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2018

Melanoma - Pipeline by Aduro BioTech Inc, H1 2018

Melanoma - Pipeline by Advenchen Laboratories LLC, H1 2018

Melanoma - Pipeline by Aeglea BioTherapeutics Inc, H1 2018

Melanoma - Pipeline by Affichem SA, H1 2018

Melanoma - Pipeline by AGV Discovery SAS, H1 2018

Melanoma - Pipeline by AIMM Therapeutics BV, H1 2018

Melanoma - Pipeline by Alkermes Plc, H1 2018

Melanoma - Pipeline by Allergy Therapeutics Plc, H1 2018

Melanoma - Pipeline by Alligator Bioscience AB, H1 2018

Melanoma - Pipeline by Altor BioScience Corp, H1 2018

Melanoma - Pipeline by Amgen Inc, H1 2018

Melanoma - Pipeline by Angimmune LLC, H1 2018

Melanoma - Pipeline by Antibe Therapeutics Inc, H1 2018

Melanoma - Pipeline by Antigen Express Inc, H1 2018

Melanoma - Pipeline by APEIRON Biologics AG, H1 2018

Melanoma - Pipeline by Apexigen Inc, H1 2018

Melanoma - Pipeline by Aphios Corp, H1 2018

Melanoma - Pipeline by Aposense Ltd, H1 2018

Melanoma - Pipeline by Aprea AB, H1 2018

Melanoma - Pipeline by Aptose Biosciences Inc, H1 2018

Melanoma - Pipeline by Arcus Biosciences Inc, H1 2018

Melanoma - Pipeline by ARMO Biosciences Inc, H1 2018

Melanoma - Pipeline by Array BioPharma Inc, H1 2018

Melanoma - Pipeline by Asana BioSciences LLC, H1 2018

Melanoma - Pipeline by Astex Pharmaceuticals Inc, H1 2018

Melanoma - Pipeline by Atreca Inc, H1 2018

Melanoma - Pipeline by aTyr Pharma Inc, H1 2018

Melanoma - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Melanoma - Pipeline by Autolus Ltd, H1 2018

Melanoma - Pipeline by Basilea Pharmaceutica Ltd, H1 2018

Melanoma - Pipeline by Batu Biologics Inc, H1 2018

Melanoma - Pipeline by Bayer AG, H1 2018

Melanoma - Pipeline by BeiGene Ltd, H1 2018

Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2018

Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Melanoma - Pipeline by BerGenBio ASA, H1 2018

Melanoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018

Melanoma - Pipeline by Biocad, H1 2018

Melanoma - Pipeline by Biogazelle NV, H1 2018

Melanoma - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018

Melanoma - Pipeline by BioLineRx Ltd, H1 2018

Melanoma - Pipeline by Bionomics Ltd, H1 2018

Melanoma - Pipeline by BioNTech AG, H1 2018

Melanoma - Pipeline by Biothera Pharmaceutical Inc, H1 2018

Melanoma - Pipeline by Biovista Inc, H1 2018

Melanoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Melanoma - Pipeline by Boston Biomedical Inc, H1 2018

Melanoma - Pipeline by BrightPath Biotherapeutics Co Ltd, H1 2018

Melanoma - Pipeline by Bristol-Myers Squibb Co, H1 2018

Melanoma - Pipeline by Calithera Biosciences Inc, H1 2018

Melanoma - Pipeline by Can-Fite BioPharma Ltd, H1 2018

Melanoma - Pipeline by CBT Pharmaceuticals Inc, H1 2018

Melanoma - Pipeline by CCRP Therapeutics GmbH, H1 2018

Melanoma - Pipeline by Celgene Corp, H1 2018

Melanoma - Pipeline by Celldex Therapeutics Inc, H1 2018

Melanoma - Pipeline by Cellestia Biotech AG, H1 2018

List of Figures

Number of Products under Development for Melanoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4D Pharma PLC
  • 4P-Pharma SAS
  • 4SC AG
  • AB Science SA
  • AbbVie Inc
  • Abivax SA
  • Adaptimmune Therapeutics Plc
  • Aduro BioTech Inc
  • Advenchen Laboratories LLC
  • Aeglea BioTherapeutics Inc
  • Affichem SA
  • AGV Discovery SAS
  • AIMM Therapeutics BV
  • Alkermes Plc
  • Allergy Therapeutics Plc
  • Alligator Bioscience AB
  • Altor BioScience Corp
  • Amgen Inc
  • Angimmune LLC
  • Antibe Therapeutics Inc
  • Antigen Express Inc
  • APEIRON Biologics AG
  • Apexigen Inc
  • Aphios Corp
  • Aposense Ltd
  • Aprea AB
  • Aptose Biosciences Inc
  • Arcus Biosciences Inc
  • ARMO Biosciences Inc
  • Array BioPharma Inc
  • Asana BioSciences LLC
  • Astex Pharmaceuticals Inc
  • Atreca Inc
  • aTyr Pharma Inc
  • Aurigene Discovery Technologies Ltd
  • Autolus Ltd
  • Basilea Pharmaceutica Ltd
  • Batu Biologics Inc
  • Bayer AG
  • BeiGene Ltd
  • Beijing Kawin Technology Share-Holding Co Ltd
  • Bellicum Pharmaceuticals Inc
  • BerGenBio ASA
  • Biocad
  • Bio-Cancer Treatment International Ltd
  • Biogazelle NV
  • Biohaven Pharmaceutical Holding Company Ltd
  • BioLineRx Ltd
  • Bionomics Ltd
  • BioNTech AG
  • Biothera Pharmaceutical Inc
  • Biovista Inc
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • BrightPath Biotherapeutics Co Ltd
  • Bristol-Myers Squibb Co
  • Calithera Biosciences Inc
  • Can-Fite BioPharma Ltd
  • CBT Pharmaceuticals Inc
  • CCRP Therapeutics GmbH
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Cellestia Biotech AG
  • Celprogen Inc
  • Celyad SA
  • Checkmate Pharmaceuticals Inc
  • Checkpoint Therapeutics Inc
  • Chipscreen Biosciences Ltd
  • Chugai Pharmaceutical Co Ltd
  • Corvus Pharmaceuticals Inc
  • Curevac AG
  • CytomX Therapeutics Inc
  • Cytori Therapeutics Inc
  • CytoVac AS
  • Cytune Pharma SAS
  • CyTuVax BV
  • CZ BioMed Corp
  • Daiichi Sankyo Co Ltd
  • Debiopharm International SA
  • DEKK-TEC Inc
  • DNAtrix Inc
  • Dynavax Technologies Corp
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Elsalys Biotech SA
  • Ensol Biosciences Inc
  • EntreChem SL
  • eTheRNA Immunotherapies NV
  • Exelixis Inc
  • Exicure Inc
  • F. Hoffmann-La Roche Ltd
  • Faron Pharmaceuticals Oy
  • Fountain Biopharma Inc
  • Galapagos NV
  • Galderma SA
  • Galectin Therapeutics Inc
  • Genelux Corp
  • Genentech Inc
  • Genexine Inc
  • Genmab A/S
  • Genocea Biosciences Inc
  • GlaxoSmithKline Plc
  • GTx Inc
  • Hadasit Medical Research Services and Development Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Heat Biologics Inc
  • Hemispherx Biopharma Inc
  • Hercules Pharmaceuticals BV
  • Histogen Inc
  • HitGen LTD
  • Horizon Pharma Plc
  • Humanigen Inc
  • ID Pharma Co Ltd
  • Idera Pharmaceuticals Inc
  • Ignyta Inc
  • Immodulon Therapeutics Ltd
  • Immune Design Corp
  • Immune Response BioPharma Inc
  • Immunicum AB
  • Immunocore Ltd
  • ImmunoGen Inc
  • Immunomedics Inc
  • Immutep Ltd
  • Imugene Ltd
  • Incyte Corp
  • Infinity Pharmaceuticals Inc
  • Inovio Pharmaceuticals Inc
  • InteRNA Technologies BV
  • IO Biotech ApS
  • Iovance Biotherapeutics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Jounce Therapeutics Inc
  • Karus Therapeutics Ltd
  • Karyopharm Therapeutics Inc
  • Kineta Inc
  • Kite Pharma Inc
  • Kringle Pharma Inc
  • K-Stemcell Co Ltd
  • Leap Therapeutics Inc
  • Lentigen Technology Inc
  • Lixte Biotechnology Holdings Inc
  • Loxo Oncology Inc
  • Lupin Ltd
  • Lytix Biopharma AS
  • MacroGenics Inc
  • Madrigal Pharmaceuticals Inc
  • MaxiVAX SA
  • MediaPharma SRL
  • Medicenna Therapeutics Corp
  • MediciNova Inc
  • MedImmune LLC
  • Medy-Tox Inc
  • MELEMA Pharma GmbH
  • Merck & Co Inc
  • Merck KGaA
  • MetaMax Ltd
  • Moderna Therapeutics Inc
  • Molecular Templates Inc
  • Moleculin Biotech Inc
  • Morphotek Inc
  • NanoVector Inc
  • NantKwest Inc
  • Nektar Therapeutics
  • Neonc Technologies Inc
  • Nerviano Medical Sciences Srl
  • NewLink Genetics Corp
  • NormOxys Inc
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Omeros Corp
  • Oncology Research International Ltd
  • Oncolys BioPharma Inc
  • OncoNOx ApS
  • OncoResponse Inc
  • OncoSec Medical Inc
  • OncoTartis Inc
  • Oncovir Inc
  • Opsona Therapeutics Ltd
  • Oxford BioTherapeutics Ltd
  • Pacific Northwest Biotechnology LLC
  • Patrys Ltd
  • PCI Biotech Holding ASA
  • PepVax Inc
  • Pfizer Inc
  • Pharmicell Co Ltd
  • Philogen SpA
  • PinCell srl
  • Pivotal BioSciences Inc
  • Plexxikon Inc
  • Polaris Pharmaceuticals Inc
  • Polyplus-Transfection SA
  • Primevax Immuno Oncology Inc
  • Promore Pharma
  • Propanc Biopharma Inc
  • Provectus Biopharmaceuticals Inc
  • Provenance Biopharmaceuticals Corp
  • Qu Biologics Inc
  • Rafael Pharmaceuticals Inc
  • Reata Pharmaceuticals Inc
  • Recombio SL
  • Regeneron Pharmaceuticals Inc
  • Replimune Ltd
  • Rexahn Pharmaceuticals Inc
  • Rgenix Inc
  • Rubicon Biotechnology Inc
  • RXi Pharmaceuticals Corp
  • Sanofi
  • SATT North SAS
  • Scancell Holdings Plc
  • Seres Therapeutics Inc
  • SilaGene Inc
  • Sillajen Biotherapeutics
  • Sino Biopharmaceutical Ltd
  • SolaranRx Inc
  • Sorrento Therapeutics Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Susavion Biosciences Inc
  • SuviCa Inc
  • Syndax Pharmaceuticals Inc
  • Synthon Holdings BV
  • Syntrix Biosystems Inc
  • Tactiva Therapeutics LLC
  • Taiga Biotechnologies Inc
  • Takara Bio Inc
  • Takis Srl
  • Targovax ASA
  • TC BioPharm Ltd
  • Theravectys SA
  • Tikcro Technologies Ltd
  • TILT Biotherapeutics Ltd
  • Tocagen Inc
  • Tolero Pharmaceuticals Inc
  • TREAT U SA
  • Trillium Therapeutics Inc
  • UbiVac LLC
  • Ultimovacs AS
  • Vaccibody AS
  • Valo Therapeutics Oy
  • Vascular Biogenics Ltd
  • Vault Pharma Inc
  • Vichem Chemie Research Ltd
  • Viralytics Ltd
  • ViraTherapeutics GmbH
  • VLP Therapeutics LLC
  • WntResearch AB
  • X4 Pharmaceuticals Inc
  • Xencor Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll